[HTML][HTML] DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Y Handelsman, JE Anderson, GL Bakris… - Metabolism, 2024 - Elsevier
The spectrum of cardiorenal and metabolic diseases comprises many disorders, including
obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular …

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

FK Knop, VR Aroda, RD do Vale, T Holst-Hansen… - The Lancet, 2023 - thelancet.com
Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

Obesity-related kidney disease: current understanding and future perspectives

FF Kreiner, PA Schytz, HJL Heerspink, BJ von Scholten… - Biomedicines, 2023 - mdpi.com
Obesity is a serious chronic disease and an independent risk factor for the new onset and
progression of chronic kidney disease (CKD). CKD prevalence is expected to increase, at …

A big STEP for treatment of heart failure with preserved ejection fraction

S Verma, BA Borlaug, J Butler, MJ Davies, DW Kitzman… - Cell Metabolism, 2023 - cell.com
In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart
failure-related symptoms, physical limitations, and exercise function, and reduced …

[HTML][HTML] 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study

R De Giorgi, I Koychev, AI Adler, PJ Cowen… - …, 2024 - thelancet.com
Background While semaglutide, approved for type-2 diabetes mellitus (T2DM), is being
investigated as a treatment for brain disorders, concerns over adverse neuropsychiatric …

Inflammation in obesity-related HFpEF: the STEP-HFpEF program

S Verma, MC Petrie, BA Borlaug, J Butler… - Journal of the American …, 2024 - jacc.org
Background Inflammation is thought to be an important mechanism for the development and
progression of obesity-related heart failure with preserved ejection fraction (HFpEF). In the …

Can fecal microbiota transplantations modulate autoimmune responses in type 1 diabetes?

CM Fuhri Snethlage, D de Wit… - Immunological …, 2024 - Wiley Online Library
Summary Type 1 diabetes (T1D) is a chronic autoimmune disease targeting insulin‐
producing pancreatic beta cells. T1D is a multifactorial disease incorporating genetic and …

GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage

B Park, E Bakbak, H Teoh… - American Journal …, 2024 - journals.physiology.org
Atherosclerotic cardiovascular disease is a chronic condition that often copresents with type
2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin …

Impact of BMI and comorbidities on efficacy of once‐weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial

BM McGowan, A Houshmand‐Oeregaard… - …, 2023 - Wiley Online Library
Objective This study assessed the effects of semaglutide on body weight, cardiometabolic
risk factors, and glycemic status in individuals categorized by baseline BMI with or without …

Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical …

DCD Hope, S Ansari, S Choudhury… - Diabetes, Obesity …, 2024 - Wiley Online Library
Aims To determine whether a continuous infusion of a glucagon‐like peptide receptor (GLP‐
1R)/glucagon receptor (GCGR) co‐agonist, G3215 is safe and well tolerated in adults with …